Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III rollover study of weekly LB03002 (somatropin) in adults with growth hormone deficiency
2006-002278-24Phase 3Completed
- Sponsor
- BioPartners
- Start
- Aug 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Eutropin Plus in growth hormone deficiency (GHD), sponsored by BioPartners. Primary endpoint: Long-term safety of LB03002 over 1 year. Started Aug 2006; status: completed.
02
Drugs
Eutropin Plus
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2006-002278-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002278-24.